The molecular characterisation of vaccine trials using recombinant envelope immunogens and live SIV containing distinct nef genes.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

The molecular characterisation of vaccine trials using recombinant envelope immunogens and live SIV containing distinct nef genes.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 54. Unique Identifier : AIDSLINE PRIM11/94191649
Almond N; Rud E; Kent K; Chan L; Page M; Jones W; Mills K; Clarke B; Kitchin P; Stott J; NIBSC, Potters Bar, United Kingdom.

Abstract: The effect of pre-existing anti-envelope immunity on the evolution of the SIVenv gene in vivo has been studied in immunised macaques, which were not protected upon challenge with SIVmav32H. Cynomolgus macaques have now been immunised with envelope immunogens derived from SIV clones homologous with or heterologous to SIVmac32H (J5 clone). Previous studies, in macaques challenged with virus pools suggested that the evolution of the V1 region of gp120 was affected by pre-immunisation. The results of the current studies on the sequence of the proviral env gene will be presented. In other studies, we have been investigating the nature of protection against superinfection, induced by live viruses in vivo. Two molecular clones, derived from SIVmac32H, differ in the sequence of the nef gene. One clone (C8) contains a 12 nucleotide deletion in nef when compared to the second clone J5. As a result, they may be distinguished using a PCR amplifying across this region. Groups of 4 cynomolgus macaques were infected with either J5 or C8 and the course of infection assessed. Nine months later these animals were challenged with the heterologous clone and the presence of each virus in the blood was determined. In both cases, the levels of superinfecting virus present in the blood was much less than in naive challenged controls. The restriction on the replication of superinfecting viruses in vivo will be discussed.

Keywords: Animal *Genes, nef Macaca fascicularis Sequence Deletion Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/GENETICS/*IMMUNOLOGY Vaccines, Synthetic/*ADMINISTRATION & DOSAGE Viral Vaccines/*ADMINISTRATION & DOSAGE ABSTRACT
940730
M9470869

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .